| CAS NO: | 1256751-11-7 |
| 包装: | 500 μg |
| 市场价: | 16632元 |
| Cas No. | 1256751-11-7 |
| 别名 | 波普瑞韦,EBP 520-d9; SCH 503034-d9 |
| Canonical SMILES | NC(C(C(CC1CCC1)NC([C@H]2N(C([C@@H](NC(NC(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O)C(C)(C)C)=O)C[C@@]3([H])[C@]2([H])C3(C)C)=O)=O)=O |
| 分子式 | C27H36D9N5O5 |
| 分子量 | 528.7 |
| 溶解度 | DMSO: Soluble,Methanol: Soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Boceprevir-d9is intended for use as an internal standard for the quantification of boceprevir by GC- or LC-MS. Boceprevir is an inhibitor of hepatitis C virus (HCV) non-structural protease 3/4A (NS3/4A; Ki= 14 nM for the HCV genotype 1b enzyme).1Boceprevir inhibits HCV replication in Huh7 cells (EC50= 200 nM).2It also inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro; Ki= 1.8 µM) and reduces cytopathic effects of SARS-CoV-2 in Vero cells (EC50= 1.31 µM).3Formulations containing boceprevir have been used in the treatment of HCV. 1.Malcolm, B.A., Liu, R., Lahser, F., et al.SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cellsAntimicrob. Agents Chemother.50(3)1013-1020(2006) 2.Maren, T.H.Carbonic anhydrase: Chemistry, physiology, and inhibitionPhysiol. Rev.47(4)595-781(1967) 3.Ma, C., Sacco, M.D., Hurst, B., et al.Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main proteaseCell Res.30(8)678-692(2020) |
m.cnreagent.com